J.P. Morgan Healthcare Conference

Generative AI and Adaptive Trials Shape Future Biotech Development

January 13th 2026

Ben Edwards of Avance Clinical explains how generative AI and adaptive trials speed early-stage drug development by improving data access and capital efficiency.

Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays

ByFeliza Mirasol

January 12th 2026

As the J.P. Morgan Healthcare Conference gets underway, Lonza’s Michael De Marco weighs in on regional manufacturing shifts as biotech pipelines mature, signaling new therapy launches within 12–18 months.

Transforming Cell Therapy with Precise Human Biology Replication (Part 2)

ByFeliza Mirasol

January 12th 2026

In part two of an interview, Daniel Delubac, iOrganBio CEO, explains how digitized, in-vitro human biology models aim to improve preclinical drug testing.

Why AI-Native Cell Manufacturing Is the Future of Drug Discovery (Part 1)

ByFeliza Mirasol

January 9th 2026

AI-driven human cell models aim to replace animal testing and deliver more accurate, data-driven insights, says iOrganBio CEO Daniel Delubac ahead of the J.P. Morgan Healthcare Conference.